SPDR Gold Trust vs Illumina, Inc. — how do they compare? SPDR Gold Trust trades at $405.27, while Illumina, Inc. trades at $190.32 (market cap $29.12B). The key difference: Illumina, Inc. is trading nearer its 52-week high, SPDR Gold Trust nearer its low. Which is the better fit depends on your goals.
| GLD | ILMN | |
|---|---|---|
52-Week High | $495.90 | $205.10 |
52-Week Low | $305.27 | $91.00 |
Market Cap | — | $29.12B |
Sector | — | Health |
Enterprise Value | — | $30.48B |
Signals from Pluang's Aura AI — not financial advice
GLD, the SPDR Gold Shares ETF, trades at $405.25, up 0.65% today, reflecting strong momentum as gold benefits from cooling U.S. inflation data and safe-haven demand. The technical outlook is bullish with moving averages supporting upward trends, though oscillators signal overbought conditions. Recent news highlights gold's resilience amid geopolitical tensions and central bank buying, with spot gold surpassing $4,438 per ounce after July's CPI report showed a 2.5% annual core increase (Kitco, 2026-08-12).
The outlook for GLD remains positive driven by macroeconomic support, but risks include potential Fed policy shifts and profit-taking pressure. Investors may see opportunities in gold's role as a hedge, though high RSI levels suggest near-term volatility. Key resistance at $407 could test further gains, while support lies at $396.
Illumina (ILMN) trades at $191.79, up 2.04% today, with a neutral technical signal and strong fundamental recovery. The stock shows bullish moving averages but faces resistance near $194. Recent earnings beats and a return to profitability in 2025, with $850M net income, highlight operational turnaround. Revenue remains stable around $4.3B, supported by robust gross margins of 66.38%.
Outlook is positive with analyst consensus Buy rating and $201.58 price target, though high P/E of 35.98 poses valuation risk. Key opportunities include sequencing demand and AI partnerships, while risks involve debt levels and competitive pressures. Institutional activity is mixed, with some funds increasing stakes amid earnings momentum.
Trailing returns across standard periods
Latest headlines on both assets
GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →